Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Globe Newswire•04/08/2026•01:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.